Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Return on Invested Capital (2020 - 2023)

Tarsus Pharmaceuticals has reported Return on Invested Capital over the past 4 years, most recently at 0.52% for Q2 2023.

  • Quarterly results put Return on Invested Capital at 0.52% for Q2 2023, down 25.0% from a year ago — trailing twelve months through Jun 2023 was 0.52% (down 25.0% YoY), and the annual figure for FY2025 was 0.21%, changed.
  • Return on Invested Capital for Q2 2023 was 0.52% at Tarsus Pharmaceuticals, down from 0.33% in the prior quarter.
  • Over the last five years, Return on Invested Capital for TARS hit a ceiling of 0.02% in Q2 2021 and a floor of 0.52% in Q2 2023.
  • Median Return on Invested Capital over the past 4 years was 0.27% (2022), compared with a mean of 0.23%.
  • Biggest five-year swings in Return on Invested Capital: rose 29bps in 2021 and later fell -25bps in 2022.
  • Tarsus Pharmaceuticals' Return on Invested Capital stood at 0.36% in 2020, then skyrocketed by 81bps to 0.07% in 2021, then tumbled by -309bps to 0.29% in 2022, then tumbled by -79bps to 0.52% in 2023.
  • The last three reported values for Return on Invested Capital were 0.52% (Q2 2023), 0.33% (Q1 2023), and 0.29% (Q4 2022) per Business Quant data.